Abbisko Cayman Ltd (2256)

Abbisko Cayman Limited engages in the research and development of pharmaceutical products in the People’s Republic of China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor in NDA/commercial trial for the treatment of tenosynovial giant cell tumors, as well as chronic graft versus host disease and solid tumors. It is also developing pivotal trial products comprising Mavorixafor (ABSK081), a CXCR4 modulator to treat warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome; and Irpagratinib (ABSK011), a small molecule inhibitor of FGFR4 for the treatment of advanced hepatocellular carcinoma. In addition, the company develops products in Phase Ib/II trial, such as Fexagratinib (ABSK091) for the treatment of urothelial carcinoma; ABSK061, a small molecule inhibitor targeting FGFR 2/3 to treat solid tumors and achondroplasia; and ABSK043, a PD-L1 inhibitor for the treatment of non-small cells lung cancer (NSCLC). Further, it is developing products in Phase I/Ia trial comprising ABSK121, a small molecule FGFR inhibitor that targets both wild-type and mutations of FGFR1-3 to treat solid tumors; ABSK112, an EGFR Exon20ins inhibitor for the treatment of NSCLC; and ABSK051, a small molecule CD73 inhibitor to treat various tumor types, such as lung and pancreatic cancer, as well as IND-stage trial products, including ABSK012, a small molecule FGFR4 inhibitor for treatment of rhabdomyosarcoma, advanced solid tumors, and soft tissue sarcoma; ABK3376, an EGFR inhibitor to treat NSCLC harboring the EGFR-C797S mutation; and ABK131, a selective MTA-cooperative and brain-penetrant PRMT5 inhibitor for the treatment of solid tumors. Additionally, the company's pre-clinical pipeline products comprise P017, P018, ASBK141, P021, P019, and P020 to treat solid tumors; and P151 for non-oncology indications. Abbisko Cayman Limited was founded in 2016 and is headquartered in Shanghai, the People’s Republic of China.